Related Experiment Video
Updated: Jun 15, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Topoisomerase 2 alpha and the case for individualized breast cancer therapy
Ronan W Glynn1, Nicola Miller, Maria C Whelan
1Department of Surgery, National University of Ireland, Galway, Clinical Science Institute, Costello Road, Galway, Ireland.
Background:
Many patients with breast cancer receive no benefit from their treatment. This has led to a search for novel therapeutic targets whose identification may facilitate a more tailored approach, thereby avoiding unnecessary toxicity. Of these, topoisomerase 2 alpha (TOP2A), located at the HER2/neu amplicon on chromosome 17, has generated particular interest because its expression has been shown to correlate with response to anthracycline-based therapies.
Methods:
We evaluated the relationship between TOP2A and its collocated gene, HER2/neu, and summarized the evidence for and against confining anthracycline-based therapies to those patients who demonstrate increased expression or amplification of these targets.
Results:
The emerging consensus supports the restriction of anthracyclines to those patients who are HER2/neu positive, with the evidence suggesting that alterations in the status of TOP2A are almost completely restricted to this group of patients.
Conclusions:
It seems increasingly likely that response to anthracyclines is predicated on these alterations.
Insights
Restricting anthracycline therapies to HER2-positive breast cancer patients with TOP2A alterations improves treatment efficacy. This targeted approach minimizes toxicity by ensuring only responsive patients receive these potent treatments.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Many breast cancer patients do not benefit from current treatments, leading to a need for targeted therapies.
- Topoisomerase 2 alpha (TOP2A) is a potential therapeutic target due to its correlation with response to anthracycline therapies.
- TOP2A is located at the HER2/neu amplicon on chromosome 17.
Purpose of the Study:
- To evaluate the relationship between TOP2A and HER2/neu gene expression.
- To summarize evidence for and against targeting anthracycline therapy based on TOP2A and HER2/neu expression.
Main Methods:
- Correlation analysis of TOP2A and HER2/neu gene status.
- Evidence synthesis on anthracycline therapy response.
Main Results:
- A consensus is emerging to restrict anthracycline use to HER2-positive patients.
- TOP2A alterations are predominantly found in HER2-positive patients.
Conclusions:
- Response to anthracyclines is likely dependent on TOP2A alterations.
- Targeting anthracyclines to HER2-positive patients with TOP2A alterations may optimize treatment outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase